Halozyme Licenses Drug Delivery Tech to Vertex

Halozyme has licensed its drug delivery technology to Vertex Pharmaceuticals for an upfront payment of $15 million. This agreement allows Vertex to utilize Halozyme's platform to enhance its drug development programs. The licensing deal represents a significant revenue stream for Halozyme and validates the utility of its technology. It also signifies Vertex's strategic interest in improving the delivery of its therapeutic candidates.